{"filings":[{"id":99640,"accession_number":"0001493152-26-021306","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Oncotelic completes merger transferring patent portfolio to Lunai for $20M Series B Preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Oncotelic contributed patent portfolio to Neurobridge Holdings, which merged into Lunai subsidiary; Oncotelic received 5 Series B shares (stated value $12.5M).","Shares convertible at $1.50/common, but conversion requires stockholder approval; no conversion allowed before approval.","Oncotelic retains perpetual, exclusive, royalty-free license to use the patents except for Biodefense and Alzheimer's fields.","Oncotelic agreed to issue 10% of fully diluted shares to Autotelic upon uplisting in exchange for assets including peptide Y, PTH, insulin formulations.","All transactions completed May 1, 2026; no cash exchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99639,"accession_number":"0001493152-26-016981","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic Therapeutics Reports FY 2025 Net Income of $249M Driven by JV Fair Value Gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income attributable to Oncotelic was $249.3M in FY 2025, compared to net loss of $4.5M in FY 2024.","Non-cash gain of $365.4M from fair value increase in GMP Bio JV investment, partially offset by $111.6M deferred tax provision.","JV subsidiaries Sapu Bio and Sapu Nano formalized; OT-101 Phase 1 combo trial completed and Phase 2/3 pancreatic cancer enrolling.","Deciparticle nanoparticle platform advancing six candidates; everolimus trial enrolling in Australia, INDs expected for palbociclib and docetaxel in 2026.","PDAOAI AI platform expanded to over 100,000 curated abstracts, contributing to seven peer-reviewed publications in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99638,"accession_number":"0001493152-26-014831","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oncotelic partners with TechForce Robotics to develop AI-enhanced GMP robotics platform","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Joint development, manufacturing, and licensing agreement signed March 31, 2026.","Combines Oncotelic's proprietary PDAOAI platform with TechForce's robotics hardware.","Platform targets GMP-compliant automated material handling, monitoring, and compliance workflows.","Financial terms not disclosed; revenue sharing and royalties to be negotiated in future agreement.","AI foreground IP owned by Oncotelic; jointly developed IP jointly owned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115761,"accession_number":"0001493152-26-013503","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.","Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.","Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.","Sapu Nano seeking strategic partnerships to accelerate development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115760,"accession_number":"0001493152-26-013391","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic subsidiary Sapu Nano to present everolimus tissue-toxicity data at SOT 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Sapu Nano (Oncotelic minority interest) to present everolimus toxicology poster at SOT 2026 in San Diego on Mar 23.","Presentation (#3539, board K692) focuses on tissue concentration-driven effects beyond traditional plasma pharmacokinetics.","Data aims to inform improved delivery strategies for mTOR inhibitors, including IV and nanoparticle formulations.","Oncotelic (OTLC) holds minority stake in Sapu Nano; no financial terms or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115759,"accession_number":"0001493152-26-004237","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.","Note convertible at $0.07/share; also issued 1,422,613 warrants at $0.15/share and 1,600,446 commitment shares.","Note secured against company assets excluding certain JV assets (OT-101, CA4P, Oxi4503, AI technologies).","Proceeds designated for general working capital; prepayment allowed with 3 trading days' notice.","Shares issuable upon conversion/exercise not registered; registration rights agreement filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115758,"accession_number":"0001493152-26-003606","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Oncotelic Therapeutics grants CEO up to 26,512 Series A preferred shares based on capital structure milestones","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Vuong Trieu receives 4,426 preferred shares (convertible to 4.426M common) for first milestone: converting $2.175M 2023 PPM Notes into 2025 Units.","Remaining 22,086 preferred shares vest upon three milestones: $350K debt from Mast Hill Fund with $45M market cap, conversion of $3.3M Autotelic loans, and repayment of $2.175M notes.","Each preferred share converts into 1,000 common shares; total potential dilution up to 26.512M common shares (approx. 4.99% of outstanding).","Agreement includes accelerated vesting upon termination without cause or change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115757,"accession_number":"0001493152-26-000821","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic lowers CEO milestone threshold from $100M to $45M market cap for stock vesting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces first market cap milestone for CEO Vuong Trieu's restricted stock from $100M to $45M.","Similar amendment with Jefferson Capital Ventures LLC lowers its milestone threshold to $45M.","Company states changes are to support progress including equity line with Mast Hills and uplisting efforts.","Other terms and milestones of the restricted stock agreements remain unchanged.","CEO's preferred stock award is tied to the same reduced milestone; no dilution details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115756,"accession_number":"0001493152-26-000619","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Oncotelic lowers market cap milestone for Jefferson Capital from $100M to $45M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces first milestone threshold in independent contractor agreement from $100M to $45M market cap.","Contractor Jefferson Capital Ventures eligible to earn restricted stock upon achieving new $45M milestone.","Amendment aims to facilitate progress on equity line with Mast Hills, AGP financing, and uplisting.","No other terms of the milestone or ICA were changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115755,"accession_number":"0001493152-26-000613","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic completes Tranche 3 of unit offering, raising $1.1M from 22 investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 44 units under final Tranche 3; each unit includes a $25,000 principal, 12% 2-year convertible note.","Each note convertible into 250,000 shares of Oncotelic at $0.10 or 25,000 EdgePoint shares at $1.00.","Each unit includes 250,000 warrants to purchase Oncotelic stock at $0.12 or EdgePoint warrants at $1.25.","Prior 2023 PPM notes settled; existing warrants extended to two years from final closing.","Registration Rights Agreement executed for shares and warrants issued in the financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132184,"accession_number":"0001493152-25-029634","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes initial $800K convertible note offering at 12% with warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 32 units at $25,000 each to 21 accredited investors; total $800,000 raised.","Each unit consists of a 2-year 12% note convertible into Oncotelic stock at $0.10/share or EdgePoint AI stock at $1.00/share.","Each unit also includes warrants to buy 250,000 Oncotelic shares at $0.12 or 25,000 EdgePoint warrants at $1.25.","Offering allows up to 500 units ($12.5M); prior 2023 PPM note exchanged as part of deal.","Registration rights granted for shares issuable under the units and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132183,"accession_number":"0001493152-25-028921","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic launches PDAOAI platform and opens TGF-β corpus access","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched PDAOAI, an evidence-interrogation platform for extracting biological signals from large datasets without training custom LLMs.","Providing open access to a TGF-β literature corpus of over 125,000 PubMed abstracts via a dedicated Discord research channel.","Platform aims to enable researchers to analyze complex biomedical data without proprietary data training."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132182,"accession_number":"0001493152-25-026883","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Oncotelic closes initial 11 units of up to 500-unit offering with 12% notes and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of 11 units at $25,000 each in best-efforts offering of up to 500 units.","Each unit includes a $25,000 note bearing 12% annual interest, due 2 years after final closing.","Notes convertible into OTLC common at $0.10/share or EdgePoint AI common at $1.00/share.","Each unit includes 250,000 warrants to buy OTLC common at $0.12/share or 25,000 EdgePoint warrants at $1.25/share.","Minimum of 10 units required; funds held in escrow until minimum met; offering exempt under Reg D Rule 506."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132181,"accession_number":"0001493152-25-018877","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEO Vuong Trieu presented at LD Micro conference on Oct 21; specifics not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Vuong Trieu presented a corporate presentation at LD Micro in San Diego on October 21, 2025.","Exhibit 99.1 containing the presentation is attached but its content was not reproduced in this filing.","No financial results, clinical updates, or guidance changes were provided in the 8-K text.","This is a procedural 8.01 announcement of an investor presentation; no material operational detail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148754,"accession_number":"0001641172-25-023189","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic Therapeutics enters consulting agreements with Jefferson Capital and Valor Nation for strategic services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Jefferson Capital Ventures and Valor Nation for 18-month consulting and advisory services starting August 6, 2025.","Jefferson receives $20,000/month cash and up to 20,320,930 restricted stock awards tied to milestones: market cap >$100M, $10M equity increase, uplisting.","Valor receives 4,064,586 shares of common stock immediately upon signing.","Jefferson's RSAs vest in thirds per milestone; unvested shares forfeited if milestones not achieved.","Shares issued under Section 4(a)(2) exemption from Securities Act registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148753,"accession_number":"0001641172-25-022361","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Oncotelic secures $560K convertible note from Mast Hill; enters $25M equity purchase agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $560,000 convertible promissory note to Mast Hill Fund, 10% OID, 10% interest, convertible at $0.07/share.","Note warrants issued for 2,000,000 shares at $0.15 exercise price; note secured against most company assets.","Also entered $25M equity purchase agreement with Mast Hill; issued warrants for 3,350,000 shares.","Equity purchase price set at 97% of market price or 102% of market alternative price; commitment period up to 24 months.","Proceeds from note for general working capital; registration rights agreements filed for resale of underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184916,"accession_number":"0001641172-25-000537","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic announces successful Phase 1 of OT-101/IL-2 for solid tumors; plans combo studies with checkpoint inhibitors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial (NCT04862767) of OT-101 + IL-2 in advanced solid tumors shows tolerable safety, no unexpected signals.","Based on safety data, Oncotelic plans to advance OT-101 + IL-2 into studies with checkpoint inhibitors (e.g., PD-1 blockers) for lung, melanoma, colorectal cancers.","OT-101 is also in Phase 3 STOP-PC study for pancreatic cancer and has shown activity in gliomas.","CEO Dr. Vuong Trieu presented on TGFβ2's role in immune suppression at SWCR 2025 conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184915,"accession_number":"0001493152-25-000028","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.","No definitive agreement reached; extension allows continued due diligence and documentation.","Both companies mutually agreed extension is in best interests; transaction remains conditional and not guaranteed.","Extension letter executed December 31, 2024; no other term sheet modifications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237390,"accession_number":"0001493152-24-016839","cik":908259,"company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.","Transaction includes Oncotelic's CA4P clinical-stage necroptosis therapies and AI tech for immunotherapy combos.","Mosaic to fund $2.0-$2.5M annual development budget; Oncotelic to loan short-term operational costs until June 1, 2024.","If Oncotelic cannot help raise $2M for Mosaic, transaction may become reverse merger.","Parties to negotiate definitive agreement; closing subject to customary due diligence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":26136441.24,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}